UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): ~~January~~February 285, 2026

INTELLIGENT BIO SOLUTIONS INC.

(Exact name of registrant as specified in its charter)

Delaware

001-39825

82-1512711

(State of

Incorporation)

(Commission

File Number)

(IRS employer

identification no.)

135 West, 41st Street, 5th Floor

New York, NY 10036

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (646) 828-8258

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value		INBS		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 72.0102 ~~Regulation~~Results FDof ~~Disclosure~~Operations and Financial Condition.

On ~~January~~February 285, 2026, Intelligent Bio Solutions Inc. (the “Company”), issued a press release (the “Press Release”) announcing ~~the~~preliminary, ~~commencement~~unaudited ofrevenue ~~its~~results ~~clinical study program to support its new FDA 510(k) submission~~ for ~~U.S.~~the ~~market~~fiscal ~~clearance~~second ofquarter ~~its~~ended ~~Intelligent Fingerprinting~~December ~~Drug~~31, ~~Screening System for detection of the opiate codeine~~2025. A copy of the Press Release is ~~attached~~furnished ~~hereto~~ as Exhibit 99.1 ~~and~~ isto ~~incorporated~~this ~~herein~~Current byReport ~~reference.~~on ~~The~~Form ~~foregoing disclosure is qualified in its entirety by the full text of the Press Release~~8-K.

The information contained herein and in ~~Item~~the ~~7.01~~accompanying exhibits shall not be incorporated by reference into any filing of ~~this~~the ~~Current~~Company, whether ~~Report~~made onbefore ~~Form~~or ~~8-K~~after the date hereof, ~~including~~regardless ~~Exhibit~~of 99any general incorporation language in such filing, unless expressly incorporated by specific reference to such filing.1 The information in this report, isincluding ~~being~~the ~~furnished~~exhibit ~~and~~hereto, shall not be deemed to be “filed” for ~~the~~purposes ~~purpose~~of Section 18 of the Securities Exchange Act of 1934, as amended ~~(the “Exchange Act”)~~, ~~nor~~or ~~shall it~~otherwise besubject ~~deemed~~to ~~incorporated~~the byliabilities ~~reference~~of inthat ~~any~~section or ~~filing~~Sections ~~under~~11 ~~the~~and ~~Exchange~~12(a)(2) ~~Act~~of or the Securities Act of 1933, as amended~~, unless specifically identified therein as being incorporated by reference~~.

Item 9.01 Financial Statements and Exhibits.

No.		Description
99.1		Press ~~Release,~~release dated ~~January~~February 285, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 28, 2026
Date: February 5, 2026
	INTELLIGENT BIO SOLUTIONS INC.
	By:	/s/ Spiro Sakiris
	Name:	Spiro Sakiris
	Title:	Chief Financial Officer

Filing Compare · INTELLIGENT BIO SOLUTIONS INC.